Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.

Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.

View in: PubMed

subject areas

Aged
Aminobutyrates
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Biphenyl Compounds
Chronic Disease
Clinical Trials as Topic
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Drug Combinations
Enalapril
Female
Glomerular Filtration Rate
Heart Failure
Humans
Kidney Diseases
Male
Middle Aged
Neprilysin
Renin-Angiotensin System
Tetrazoles
Treatment Outcome
Valsartan

authors with profiles

Michael R. Zile